Optimization of RGD-modified nano-liposomes encapsulating eptifibatide
IJB-Iranian Journal of Biotechnology. 2016; 14 (2): 33-40
in English
| IMEMR
| ID: emr-193910
ABSTRACT
Background:
Eptifibatide [Integrilin] is an intravenous [IV] peptide drug that selectively inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug, however has a short half-life. Therefore, antithrombotic agents like eptifibatide are required to become improved with a protected and targeted delivery system such as using nano-liposomes to the site of thrombus
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Iran. J. Biotechnol.
Year:
2016
Similar
MEDLINE
...
LILACS
LIS